{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T16:01:47Z","timestamp":1790352107551,"version":"4.1.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Open Respiratory Archives"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.opresp.2026.100666","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T23:33:51Z","timestamp":1788305631000},"page":"100666","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of Elexacaftor\/Tezacaftor\/Ivacaftor in Cystic Fibrosis Patients With Severe Lung Disease Carrying Previously Ineligible CFTR Mutations"],"prefix":"10.1016","volume":"8","author":[{"given":"Laura","family":"Carrasco-Hern\u00e1ndez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa M.","family":"Gir\u00f3n-Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amparo","family":"Sol\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Concepci\u00f3n","family":"Prados-S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Ramos-Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Victoria-Gir\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa Mar","family":"G\u00f3mez-Punter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Jos\u00e9","family":"Selma-Ferrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Olveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ester","family":"Zamarr\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Quintana-Gallego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Casilda","family":"Olveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.opresp.2026.100666_bib0130","unstructured":"Agencia espa\u00f1ola de medicamentos y productos sanitarios. Ficha t\u00e9cnica KAFTRIO 75mg\/50mg\/100mg comprimidos recubiertos con pel\u00edcula [Internet]. Available from: https:\/\/cima.aemps.es\/cima\/dochtml\/ft\/1201468001\/FT_1201468001.html. [Cited 28 July 2024]."},{"key":"10.1016\/j.opresp.2026.100666_bib0135","unstructured":"Vertex Announces FDA Approvals of TRIKAFTA\u00ae (elexacaftor\/tezacaftor\/ivacaftor and ivacaftor), SYMDEKO\u00ae (tezacaftor\/ivacaftor and ivacaftor) and KALYDECO\u00ae (ivacaftor) for use in people with CF with certain rare mutations [Internet]. 2020. https:\/\/investors.vrtx.com\/news-releases\/news-release-details\/vertex-announcesfda-approvals-trikaftar. 2023. p. 1\u201318. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/212273s004lbl.pdf. [Cited 28 July 2024]."},{"key":"10.1016\/j.opresp.2026.100666_bib0140","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jcf.2018.05.004","article-title":"CFTR modulator theratyping: current status, gaps and future directions","volume":"18","author":"Clancy","year":"2019","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.opresp.2026.100666_bib0145","series-title":"Spanish Cystic Fibrosis Registry: annual report 2021","author":"Pastor-Vivero","year":"2023"},{"key":"10.1016\/j.opresp.2026.100666_bib0150","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02774-2020","article-title":"Rescue of multiple class II CFTR mutations by elexacaftor+tezacaftor+ivacaftor mediated in part by the dual activities of elexacaftor as both corrector and potentiator","volume":"57","author":"Laselva","year":"2021","journal-title":"Eur Respir J"},{"issue":"18","key":"10.1016\/j.opresp.2026.100666_bib0155","doi-asserted-by":"crossref","first-page":"e139983","DOI":"10.1172\/jci.insight.139983","article-title":"Allosteric folding correction of F508del and rare CFTR mutants by elexacaftor\u2013tezacaftor\u2013ivacaftor (Trikafta) combination","volume":"5","author":"Veit","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.opresp.2026.100666_bib0160","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.jcf.2021.03.011","article-title":"Elexacaftor co-potentiates the activity of F508del and gating mutants of CFTR","volume":"20","author":"Veit","year":"2021","journal-title":"J Cyst Fibros"},{"issue":"Suppl. 2","key":"10.1016\/j.opresp.2026.100666_bib0165","doi-asserted-by":"crossref","first-page":"S306","DOI":"10.1016\/S1569-1993(21)02068-3","article-title":"645: Clinical response of 2 patients with N1303K mutations to CFTR modulator therapy [abstract]","volume":"20","author":"Cagnina","year":"2021","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.opresp.2026.100666_bib0170","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.arbres.2010.01.006","article-title":"Validaci\u00f3n de la versi\u00f3n espa\u00f1ola del cuestionario revisado de calidad de vida para fibrosis qu\u00edstica en adolescentes y adultos (CFQR 14+ Spain)","volume":"46","author":"Olveira","year":"2010","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.opresp.2026.100666_bib0175","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.3390\/genes12081178","article-title":"Effectiveness of elexacaftor\/tezacaftor\/ivacaftor therapy in three subjects with the cystic fibrosis genotype Phe508del\/unknown and advanced lung disease","volume":"12","author":"Terlizzi","year":"2021","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.opresp.2026.100666_bib0180","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00110-2023","article-title":"Theratyping cystic fibrosis patients to guide elexacaftor\/tezacaftor\/ivacaftor out-of-label prescription","volume":"62","author":"Dreano","year":"2023","journal-title":"Eur Respir J"},{"key":"10.1016\/j.opresp.2026.100666_bib0185","doi-asserted-by":"crossref","first-page":"828","DOI":"10.3390\/antibiotics10070828","article-title":"Elexacaftor\u2013tezacaftor\u2013ivacaftor therapy for cystic fibrosis patients with the f508del\/unknown genotype","volume":"10","author":"Comegna","year":"2021","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.opresp.2026.100666_bib0190","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.arbres.2024.04.007","article-title":"Elexacaftor\/tezacaftor\/ivacaftor effectiveness in N1303K variant in adult people with cystic fibrosis","volume":"60","author":"Gon\u00e7alves Martynychen Canan","year":"2024","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.opresp.2026.100666_bib0195","article-title":"The French compassionate programme of elexacaftor\u2013tezacaftor\u2013ivacaftor in people with cystic fibrosis with advanced lung disease and no F508del CFTR variant","volume":"61","author":"Burgel","year":"2023","journal-title":"Eur Respir J"},{"key":"10.1016\/j.opresp.2026.100666_bib0200","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.jcf.2023.06.001","article-title":"Clinical and functional efficacy of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis carrying the N1303K mutation","volume":"22","author":"Sadras","year":"2023","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.opresp.2026.100666_bib0205","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor\u2013tezacaftor\u2013ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.opresp.2026.100666_bib0210","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jcf.2013.09.007","article-title":"Sweat chloride as a biomarker of CFTR activity: proof of concept and ivacaftor clinical trial data","volume":"13","author":"Accurso","year":"2014","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.opresp.2026.100666_bib0215","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jcf.2016.02.015","article-title":"Variability of sweat chloride concentration in subjects with cystic fibrosis and G551D mutations","volume":"16","author":"Vermeulen","year":"2017","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.opresp.2026.100666_bib0220","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/S2213-2600(24)00249-2","article-title":"Expanding the indication of CFTR modulator combinations for people with cystic fibrosis with non-F508del variants","volume":"12","author":"Burgel","year":"2024","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.opresp.2026.100666_bib0225","doi-asserted-by":"crossref","first-page":"2301959","DOI":"10.1183\/13993003.01959-2023","article-title":"Gathering real-world compassionate data to expand eligibility for elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis with N1303K or other rare CFTR variants: a viewpoint","volume":"63","author":"Burgel","year":"2024","journal-title":"Eur Respir J"},{"key":"10.1016\/j.opresp.2026.100666_bib0230","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.jcf.2025.02.008","article-title":"Evaluation of the response to elexacaftor\u2013tezacaftor\u2013ivacaftor of the rare CFTR variants L383S, I507del, L1065P and R1066H in intestinal organoid-derived epithelial monolayers","volume":"24","author":"Conti","year":"2025","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.opresp.2026.100666_bib0235","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1002\/ppul.26362","article-title":"Impact of elexacaftor\/tezacaftor\/ivacaftor on bacterial cultures from people with cystic fibrosis","volume":"58","author":"Beck","year":"2023","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.opresp.2026.100666_bib0240","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.arbres.2023.05.017","article-title":"Experience with elexacaftor\/tezacaftor\/ivacaftor in patients with cystic fibrosis and advanced disease","volume":"59","author":"Carrasco Hern\u00e1ndez","year":"2023","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.opresp.2026.100666_bib0245","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1007\/s00018-022-04215-3","article-title":"Targeting the E1 ubiquitin-activating enzyme (UBA1) improves elexacaftor\/tezacaftor\/ivacaftor efficacy towards F508del and rare misfolded CFTR mutants","volume":"79","author":"Borgo","year":"2022","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.opresp.2026.100666_bib0250","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.jcf.2024.02.006","article-title":"In vitro modulator responsiveness of 655 CFTR variants found in people with cystic fibrosis","volume":"23","author":"Bihler","year":"2024","journal-title":"J Cyst Fibros"}],"container-title":["Open Respiratory Archives"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2659663626001499?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2659663626001499?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T15:14:58Z","timestamp":1790349298000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2659663626001499"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S2659663626001499"],"URL":"https:\/\/doi.org\/10.1016\/j.opresp.2026.100666","relation":{},"ISSN":["2659-6636"],"issn-type":[{"value":"2659-6636","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of Elexacaftor\/Tezacaftor\/Ivacaftor in Cystic Fibrosis Patients With Severe Lung Disease Carrying Previously Ineligible CFTR Mutations","name":"articletitle","label":"Article Title"},{"value":"Open Respiratory Archives","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.opresp.2026.100666","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Sociedad Espa\u00f1ola de Neumolog\u00eda y Cirug\u00eda Tor\u00e1cica (SEPAR). Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"100666"}}